The company offers Phase I-IV clinical trial capabilities, integrated consulting expertise, and broad therapeutic expertise to accelerate new therapies for patients.

Parexel combines in-house expertise, patient and caregiver insights, and cutting-edge technologies to plan, operationalize, and deliver DCTs for biopharmaceutical customers worldwide.

Based on its recent analysis of the global decentralized clinical trials (DCT) industry, Frost & Sullivan has recognized leading global clinical research organization (CRO) Parexel with the 2022 Global Customer Value Leadership award. 

Parexel combines in-house expertise, patient and caregiver insights, and cutting-edge technologies to plan, operationalize, and deliver DCTs for biopharmaceutical customers worldwide while ensuring the highest levels of patient safety. 

The company offers Phase I-IV clinical trial capabilities, integrated consulting expertise, and broad therapeutic expertise to accelerate new therapies for patients.

Parexel has earned a reputation of supporting its customers’ path toward minimizing patient burden while accumulating real-time, accurate clinical trial data. 

It builds its DCT solutions by collaborating closely with a range of stakeholders and partners to evolve alongside market needs and trends.